Harrow (HROW)
Commercializes branded eye medicines and ImprimisRx compounding for US ophthalmology.
Something off on this page? Send us feedback.
Sells FDA-approved ophthalmic products and runs ImprimisRx, an ophthalmology-focused compounding business. Revenue is centered on branded products, while growth depends on acquired and licensed rights, launch execution, reimbursement, and reliable manufacturing supply.
Commercializes FDA-approved ophthalmic products through the Branded segment, including IHEEZO, VEVYE, TRIESENCE and other specialty eye medicines, and operates ImprimisRx for ophthalmology-focused compounding.
The portfolio is concentrated in the United States, with selected Canadian rights and global rights to Melt assets. Expansion has come through product-rights acquisitions, licenses, and internal work rather than a broad therapeutic footprint.
Execution centers on eyecare commercial channels, supply restoration for acquired products, and preparation for biosimilar and pipeline launches. The business depends on physician adoption, reimbursement, manufacturing quality, supply-chain reliability, and regulatory compliance for labeled promotion and compounded formulations.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Target | Target: — | Target: $45 |
| May 13, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: $94 | Target: $88 |
| Mar 18, 2026 | BTIG | Reiterate | Rating: —Target: — | Target: $63 |
| Mar 4, 2026 | H.C. Wainwright | Target | Target: $64 | Target: $70 |
| Nov 11, 2025 | Cantor Fitzgerald | Target | Target: $76 | Target: $94 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $83.9M · Total debt $300.7M · Total assets $416.8M · Shareholders' equity $15.2M
- Revenue
- $70.7M
- Operating income
- −$11.0M
- Net income
- −$17.3M
No dividends on record.
| Institutions | 58.09% | 21.78M shares | |
|---|---|---|---|
| 234 holders · as of Jun 30, 2026 | |||
| Insiders | 20.32% | 7.62M shares | |
| 6 holders · as of May 19, 2026 | |||
| Other | 21.59% | 8.10M shares | |
| remainder | |||
37.49M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mark L. Baum1Insiderdirector, officer: CHIEF EXECUTIVE OFFICER | 11.88% | 4.06M | filed May 15, 2026 |
Private Capital Management, LLC (46-3167283)Institution | 9.68% | 3.63M | filed Jan 9, 2024 |
BlackRock, Inc.Institution | 7.31% | 2.74M | as of Jun 30, 2026 |
Opaleye Management Inc.Institution | 6.40% | 2.40M | as of Jun 30, 2026 |
Daniel KaufmanInsider | 5.01% | 1.88M | filed Mar 11, 2026 |
- Mark L. Baum's transaction reports restate only vehicles that traded; the 2025 ownership statement (4.06M) plus the 396.7K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Amir Shojaei | officer: CHIEF SCIENTIFIC OFFICER | −11,250 | $40.00 |
| May 18, 2026 | Lauren P. Silvernail | director | +1,000 | $31.00 |
| May 18, 2026 | Adrienne L. Graves | director | +1,000 | $31.07 |
| May 14, 2026 | Andrew R. Boll | officer: PRESIDENT AND CFO | +3,500 | $29.90 |
| May 14, 2026 | Mark L. Baum | director, officer: CHIEF EXECUTIVE OFFICER | +10,000 | $30.20 |
- Bausch + Lomb
Dry-eye and broad ophthalmic portfolio overlap
- AbbVie
Allergan eye-care brands in dry eye, retina, and glaucoma
- Alcon
Dry-eye products and surgical-suite influence
- Regeneron
EYLEA franchise anchors anti-VEGF retina competition
- Viatris
TYRVAYA adds dry-eye and ophthalmology-franchise pressure
- Ocular Therapeutix
Post-surgical steroid and retina pipeline overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Harrow | $33.97 | −1.40% | $1.28B | — | 27.3 | 4.7 | +10.9% |
| Bausch + Lomb | $17.18 | −0.81% | $6.19B | — | 17.2 | 1.2 | +9.1% |
| AbbVie | $265.99 | +0.29% | $468.77B | 74.8 | 17.5 | 7.3 | +10.2% |
| Alcon | $65.38 | −0.32% | $31.99B | 50.5 | 17.2 | 3.0 | +7.5% |
| Regeneron | $795.63 | −1.03% | $82.82B | 19.9 | 13.1 | 5.3 | +16.7% |
| Viatris | $17.15 | −0.20% | $20.01B | — | 6.7 | 1.4 | +4.9% |
| Ocular Therapeutix | $10.13 | −3.50% | $2.30B | — | — | 44.2 | +0.1% |
| Median | 50.5 | 17.2 | 4.1 | +8.3% |